Transmitted Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey

• Abstracts
• Supplementary data

Factors Affecting Risk of CVD Events in a Global CVD Prevention Cohort of People with HIV

• Abstracts
• Supplementary data

Untangling the Sources of HIV-related Cardiovascular Risk

Long-term mortality trends among individuals with tuberculosis: a retrospective cohort study of individuals diagnosed with tuberculosis in Brazil

• Abstract
• Supplementary data

Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras

• Abstract
• Supplementary data

The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic

• Abstracts

Patterns in Prescribing and Dispensing Influenza Antivirals Among Adults With Influenza Presenting to Urgent Care and Emergency Department Settings: VISION Network, 2023–2024

• Abstract
• Supplementary data

Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance

• Abstract

Real-world Human Immunodeficiency Virus RNA and Antigen/Antibody Testing Among People Who Use Long-acting Injectable Preexposure Prophylaxis

• Abstract
• Supplementary data

Changes in the Prevalence of Non-AIDS Conditions Among Hospitalized Persons With Human Immunodeficiency Virus (HIV) in the United States and Canada, 2008–2018

• Abstracts
• Supplementary data

Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa

• Abstract
• Supplementary data

Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study

• Abstract
• Supplementary data

Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes

• Abstract
• Supplementary data

Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease

• Abstract
• Supplementary data

Next-Generation Urinary LAM Assays—Are We There Yet?

• Extract

Lower Tuberculosis Incidence Among People With Human Immunodeficiency Virus Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study

• Abstracts

State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women

• Abstract

Executive Summary: State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women

• Extract

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial

• Abstracts
• Supplementary data

Antiretroviral Therapy Within 2 Years of Human Immunodeficiency Virus Acquisition Is Associated With Fewer Viral Blips: A Retrospective Analysis of More Than 20 Years of Data From the US Military HIV Natural History Study

• Abstracts